Harrow, Inc. Common Stock HROW
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERICi
Market dataready · fetched 2026-11-12T17:42:37.249Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T17:40:54.025725969Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T17:42:35.949698+00:00
Harrow, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 21.56 | 258.5% | 29.6% | |||
| 25Δ | 33.99 | 134.5% | 19.9% | 24.02 | 197.2% | 21.2% |
| 30Δ | 33.17 | 140.4% | 17.9% | 26.47 | 135.8% | 12.9% |
| 35Δ | 27.50 | 113.5% | 9.6% | |||
| 40Δ | 29.79 | 62.5% | 5.3% | 28.14 | 101.7% | 7.7% |
| 45Δ | 29.50 | 72.0% | 5.3% | 28.78 | 90.0% | 5.8% |
| 50Δ | 29.20 | 81.6% | 5.2% | 29.31 | 86.1% | 4.7% |
| 55Δ | 28.87 | 85.4% | 4.9% | 29.78 | 86.5% | 4.0% |
| 60Δ | 28.47 | 78.2% | 3.8% | 30.16 | 82.9% | 3.3% |
| 65Δ | 28.08 | 71.0% | 2.8% | 30.46 | 75.9% | 2.6% |
| 70Δ | 27.71 | 67.6% | 2.2% | 30.77 | 69.0% | 1.9% |
| 75Δ | 27.35 | 65.1% | 1.7% | 31.10 | 63.2% | 1.3% |
| 80Δ | 31.54 | 61.4% | 0.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.56
- IV
- 258.5%
- B/E move
- 29.6%
25Δ
- Pseudo strike
- 33.99
- IV
- 134.5%
- B/E move
- 19.9%
- Pseudo strike
- 24.02
- IV
- 197.2%
- B/E move
- 21.2%
30Δ
- Pseudo strike
- 33.17
- IV
- 140.4%
- B/E move
- 17.9%
- Pseudo strike
- 26.47
- IV
- 135.8%
- B/E move
- 12.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.50
- IV
- 113.5%
- B/E move
- 9.6%
40Δ
- Pseudo strike
- 29.79
- IV
- 62.5%
- B/E move
- 5.3%
- Pseudo strike
- 28.14
- IV
- 101.7%
- B/E move
- 7.7%
45Δ
- Pseudo strike
- 29.50
- IV
- 72.0%
- B/E move
- 5.3%
- Pseudo strike
- 28.78
- IV
- 90.0%
- B/E move
- 5.8%
50Δ
- Pseudo strike
- 29.20
- IV
- 81.6%
- B/E move
- 5.2%
- Pseudo strike
- 29.31
- IV
- 86.1%
- B/E move
- 4.7%
55Δ
- Pseudo strike
- 28.87
- IV
- 85.4%
- B/E move
- 4.9%
- Pseudo strike
- 29.78
- IV
- 86.5%
- B/E move
- 4.0%
60Δ
- Pseudo strike
- 28.47
- IV
- 78.2%
- B/E move
- 3.8%
- Pseudo strike
- 30.16
- IV
- 82.9%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 28.08
- IV
- 71.0%
- B/E move
- 2.8%
- Pseudo strike
- 30.46
- IV
- 75.9%
- B/E move
- 2.6%
70Δ
- Pseudo strike
- 27.71
- IV
- 67.6%
- B/E move
- 2.2%
- Pseudo strike
- 30.77
- IV
- 69.0%
- B/E move
- 1.9%
75Δ
- Pseudo strike
- 27.35
- IV
- 65.1%
- B/E move
- 1.7%
- Pseudo strike
- 31.10
- IV
- 63.2%
- B/E move
- 1.3%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 31.54
- IV
- 61.4%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 63.45% | |
| 66.98% | |
| 71.38% | |
| 64.89% | |
| 81.38% | |
| 61.16% | |
| 60.23% | |
| 56.95% | |
| 60.42% | |
| 61.86% | |
| 57.77% | |
| 57.08% | |
| 59.03% | |
| 59.18% | |
| 62.08% | |
| 65.07% | |
| 67.07% | |
| 64.13% | |
| 58.78% | |
| 64.66% | |
| 62.65% | |
| 63.79% | |
| 82.43% | |
| 81.95% | |
| 62.46% | |
| 61.72% | |
| 64.79% | |
| 62.09% | |
| 63.01% | |
| 61.94% | |
| 63.30% | |
| 69.91% | |
| 64.96% | |
| 67.50% | |
| 66.08% | |
| 69.97% | |
| 66.54% | |
| 67.39% | |
| 75.00% | |
| 69.08% | |
| 74.31% | |
| 86.95% | |
| 94.93% | |
| 94.30% | |
| 71.98% | |
| 68.34% | |
| 69.88% | |
| 72.69% | |
| 76.98% | |
| 76.63% | |
| 78.40% | |
| 81.45% | |
| 79.49% | |
| 76.70% | |
| 79.93% |
Drug Manufacturers - Specialty & Generic
INCR
Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America,…
More →IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston,…
More →KMDA
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
More →KNSA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly…
More →LFCR
Description unavailable
More →LNTH
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer…
More →